You are here: Industry Insights > Abraxane

News List

Broad-spectrum anti-cancer drug "returns" to China, and the market landscape has already changed drastically Yefenghong
May 27, 2024
Paclitaxel, a natural product extracted from taxus chinensis, acts on the microtubule to inhibit the mitosis of tumor cells and is one of the most important broad-spectrum chemotherapy drugs.
Chinese ABRAXANE® supply expected to be disrupted europeanpharmaceuticalreview
March 27, 2020
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
BeiGene Announces Supply Update for ABRAXANE® in China BeiGene
March 26, 2020
NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company; As the marketing agent for ABRAXANE in China, BeiGene is working with BMS to restore supply in China.
Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU contractpharma
August 30, 2019
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer.
FDA grants priority review to Roche's filing for Tecentriq in triple-negative breast cancer firstwordpharma
November 14, 2018
Roche said Tuesday that the FDA granted priority review to a filing seeking approval of Tecentriq (atezolizumab) plus chemotherapy for the first-line treatment of unresectable